Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. (CGEN) covers the month of June 2003. The report incorporates a press release dated June 16, 2003, and a Proxy Statement for the Annual General Meeting of Shareholders scheduled for July 30, 2003. The filing discusses the company's audited financial statements for the fiscal year ended December 31, 2002, and outlines corporate governance matters including director elections and executive compensation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the period ended December 31, 2002. It references the discussion of audited financial statements at the upcoming shareholder meeting but does not include the numerical data within this document.
Available financial data includes:
- Director Compensation (2002): Aggregate compensation paid to all directors was approximately $581,859, including $151,321 in accrued pension and severance benefits.
- Outstanding Shares: As of June 20, 2003, there were 26,268,656 Ordinary Shares outstanding.
- Share Ownership: Clal Biotechnology Industries Ltd. held 11.6% (3,045,839 shares); Martin S. Gerstel held 6.4% (1,669,888 shares); Apax (OCS) Nominees Limited held 5.3% (1,384,615 shares).
Material Changes and Strategic Developments
The most significant material change reported is the extension of the license agreement with Novartis Pharma regarding Compugen's LEADS platform.
- Novartis Agreement Extension: On June 16, 2003, Compugen announced the extension of Novartis Pharma's license for an additional year, completing the maximum three-year term of the agreement.
- New Collaboration Scope: Compugen will design a genome-wide collection of DNA probes for Novartis, leveraging expertise in transcriptome analysis, alternative splicing, and antisense phenomena.
- Executive Compensation Restructuring: The annual consulting fee of $150,000 paid to Shomar Corporation (controlled by Chairman Martin Gerstel) was discontinued for the years 2003 through 2006. This was replaced with equity-based compensation.
Guidance, Outlook, and Risks
Management Commentary: CEO Mor Amitai stated the collaboration with Novartis allows Compugen to continue developing its platforms while learning from a global leader in drug discovery. Novartis representatives expressed satisfaction with the collaboration's success in meeting milestones and feeding their drug target pipeline.
Forward-Looking Statements and Risks: The filing includes standard forward-looking statements regarding future events. Identified risks include:
- Changes in relationships with collaborators.
- Impact of competitive products and technological changes.
- Risks relating to the development of new products.
- Ability to implement technological improvements and retain customers.
Unusual Items: The filing details specific equity grants subject to shareholder ratification: 150,000 options to Martin Gerstel for consulting services, 100,000 options to Martin Gerstel for his role as Chairman, and 200,000 options to CEO Mor Amitai. All options have an exercise price of $2.38 and vest over four years.
Investor Verification Checklist
- Verify the specific financial performance metrics (revenue, net loss, cash position) for the year ended December 31, 2002, which are referenced but not detailed in this filing.
- Confirm the terms and potential revenue impact of the extended Novartis agreement and the new DNA probe design project.
- Review the dilution impact of the 450,000 new stock options granted to Chairman Gerstel and CEO Amitai.
- Assess the company's cash runway given the discontinuation of the $150,000 annual consulting fee and the shift to equity compensation.
- Monitor the outcome of the shareholder vote on the ratification of director compensation and the appointment of auditors.